+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Benign Prostatic Hypertrophy Drugs Market by Drug Class, Generic Status, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Benign Prostatic Hypertrophy Drugs Market by Drug Class, Generic Status, Distribution Channel, Dosage Form - Global Forecast to 2030- Product Image
Sale

Benign Prostatic Hypertrophy Drugs Market by Drug Class, Generic Status, Distribution Channel, Dosage Form - Global Forecast to 2030

  • PDF Icon

    Report

  • 197 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5977967
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Benign Prostatic Hypertrophy Drugs Market is advancing through a period of strategic realignment, technological progress, and evolving healthcare demands. Pharmaceutical leaders and innovators must navigate emerging opportunities and disruptions to deliver patient-centric and economically viable therapies.

Market Snapshot: Benign Prostatic Hypertrophy Drugs Market

The global benign prostatic hypertrophy drugs market grew from USD 5.50 billion in 2024 to USD 5.89 billion in 2025. With a projected CAGR of 7.00%, the market is expected to reach USD 8.26 billion by 2030. This growth is fueled by aging population trends, mounting pressure for therapeutic innovation, and an increased focus on evidence-based care.

Scope & Segmentation

  • Drug Class: Includes 5-alpha reductase inhibitors (such as Dutasteride, Finasteride), alpha blockers (Alfuzosin, Doxazosin, Silodosin, Tamsulosin, Terazosin), combination therapies (Dutasteride + Tamsulosin, Finasteride + Tamsulosin), and plant-derived phytotherapeutics (Beta-Sitosterol, Pygeum, Saw Palmetto).
  • Generic Status: Covers branded drugs (including Avodart, Flomax, Jalyn, Proscar) and generics.
  • Distribution Channel: Assesses hospital pharmacy, online pharmacy, and retail pharmacy segments.
  • Dosage Form: Evaluates capsules (extended and immediate release), tablets (extended and immediate release), and oral solutions.
  • Regions: Analyzes the Americas (with focus on major US states, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including UK, Germany, France, Russia, Italy, Spain, Middle Eastern and African nations), and Asia-Pacific (including China, India, Japan, Australia, and Southeast Asia).
  • Key Players: Reviews significant developments from Merck & Co., Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Novartis AG, Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, and Lupin Limited.

Key Takeaways for Senior Decision-Makers

  • Demographic trends and aging populations are rapidly raising demand for well-tolerated, efficient benign prostatic hypertrophy drug therapies.
  • Emerging diagnostic technologies, including biomarker-driven decision tools and advanced imaging, are reshaping both patient pathways and product development strategies.
  • The increasing adoption of real-world evidence and digital monitoring is improving adherence and driving iterative advances in therapeutic guidelines.
  • Pharmaceutical companies are leveraging alliances with biotech firms and digital health vendors to access innovative delivery systems and support services that differentiate new product offerings.
  • Regional differences are substantial: mature American markets emphasize patient support and outcome monitoring, while Asia-Pacific is fostering rapid adoption of generics and alternative phytotherapeutic options.
  • Strategic segmentation by drug class, channel, and geography aids in portfolio optimization and market positioning for both established brands and emerging players.

Tariff Impact and Supply Chain Adaptation

The 2025 introduction of United States tariff measures has led to heightened raw material and production costs, particularly for active pharmaceutical ingredients sourced globally. Market leaders are responding with diversified manufacturing strategies, shifting capacities to tariff-exempt regions, and negotiating supplier agreements to stabilize expenses. These adjustments, while fostering supply chain resilience, also intensify competitive dynamics among branded and generic manufacturers. Furthermore, broader adoption of generics in cost-sensitive segments is prompting value-focused innovations by branded drug producers.

Research Methodology & Data Sources

This report utilizes a rigorous multi-stage research approach, combining comprehensive secondary reviews of journals, regulatory filings, and company disclosures with primary interviews from senior R&D, commercial, and clinical experts. Quantitative insights are validated against proprietary datasets and industry sales volumes, while findings are peer-reviewed for analytical robustness.

Why This Report Matters

  • Enables senior leaders to navigate disruptive forces and regulatory shifts with actionable market intelligence tailored to the evolving benign prostatic hypertrophy drugs market.
  • Delivers clarity on pipeline dynamics, competitor strategies, and regional trends, supporting informed investment, go-to-market planning, and resource allocation.
  • Presents a holistic, evidence-based framework to assess new patient engagement technologies, real-world outcomes, and competitive positioning for sustained growth.

Conclusion

This analysis provides a clear framework for senior stakeholders seeking to align strategic priorities with market realities in benign prostatic hypertrophy therapeutics. By integrating innovation, operational resilience, and deeper stakeholder engagement, organizations can secure leadership and growth.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Benign Prostatic Hypertrophy Drugs Market, by Drug Class
8.1. Introduction
8.2. 5-Alpha Reductase Inhibitors
8.2.1. Dutasteride
8.2.2. Finasteride
8.3. Alpha Blockers
8.3.1. Alfuzosin
8.3.2. Doxazosin
8.3.3. Silodosin
8.3.4. Tamsulosin
8.3.5. Terazosin
8.4. Combination Therapy
8.4.1. Dutasteride + Tamsulosin
8.4.2. Finasteride + Tamsulosin
8.5. Phytotherapy
8.5.1. Beta-Sitosterol
8.5.2. Pygeum
8.5.3. Saw Palmetto
9. Benign Prostatic Hypertrophy Drugs Market, by Generic Status
9.1. Introduction
9.2. Branded
9.2.1. Avodart
9.2.2. Flomax
9.2.3. Jalyn
9.2.4. Proscar
9.3. Generic
10. Benign Prostatic Hypertrophy Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Benign Prostatic Hypertrophy Drugs Market, by Dosage Form
11.1. Introduction
11.2. Capsule
11.2.1. Extended Release
11.2.2. Immediate Release
11.3. Oral Solution
11.4. Tablet
11.4.1. Extended Release
11.4.2. Immediate Release
12. Americas Benign Prostatic Hypertrophy Drugs Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Benign Prostatic Hypertrophy Drugs Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Benign Prostatic Hypertrophy Drugs Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. GlaxoSmithKline plc
15.3.3. Teva Pharmaceutical Industries Ltd.
15.3.4. Novartis AG
15.3.5. Boehringer Ingelheim International GmbH
15.3.6. Viatris Inc.
15.3.7. Sun Pharmaceutical Industries Ltd.
15.3.8. Dr. Reddy's Laboratories Ltd.
15.3.9. Cipla Limited
15.3.10. Lupin Limited
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET MULTI-CURRENCY
FIGURE 2. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALFUZOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOXAZOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SILODOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TERAZOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DUTASTERIDE + TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FINASTERIDE + TAMSULOSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BETA-SITOSTEROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PYGEUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY SAW PALMETTO, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY AVODART, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY FLOMAX, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY JALYN, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PROSCAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ORAL SOLUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY EXTENDED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 70. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 73. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 74. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 75. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 76. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 77. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 78. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 79. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 80. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 82. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 83. CANADA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 84. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 85. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 86. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 87. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 88. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 89. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 90. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 91. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 92. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 93. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 94. MEXICO BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 121. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 122. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 130. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 131. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 132. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 133. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 134. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 135. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 136. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 137. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 138. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 140. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 141. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 142. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 143. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 144. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 145. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 146. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 147. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 148. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 149. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 150. GERMANY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 151. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 153. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 154. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 155. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 156. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 157. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 158. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 160. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 161. FRANCE BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 162. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 163. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 164. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 165. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 166. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 167. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 168. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 169. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 170. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 171. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 172. RUSSIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 173. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 174. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 175. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 176. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 177. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 178. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 179. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 180. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 182. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 183. ITALY BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 184. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 185. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 186. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 187. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 188. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 189. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 190. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 191. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 193. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 194. SPAIN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 195. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 196. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 197. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 198. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 199. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 200. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 201. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 202. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 203. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 204. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 205. UNITED ARAB EMIRATES BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 206. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 208. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 209. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 210. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 211. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 212. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 213. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 214. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 215. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 216. SAUDI ARABIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 217. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 218. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 219. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 220. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 221. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 222. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 223. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 224. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 225. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 226. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 227. SOUTH AFRICA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 228. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 229. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 230. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 231. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 232. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 233. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 234. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 235. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 237. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 238. DENMARK BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 239. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 240. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 241. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 242. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 243. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 244. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 245. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 246. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 247. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 248. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 249. NETHERLANDS BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 250. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 251. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 252. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 253. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 254. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 255. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 256. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 257. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 259. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 260. QATAR BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 261. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 262. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 264. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 265. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 266. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 267. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 268. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 269. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 270. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 271. FINLAND BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 272. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 273. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 274. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 275. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 276. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 277. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 278. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 279. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 281. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 282. SWEDEN BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 283. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 284. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY 5-ALPHA REDUCTASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 285. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY ALPHA BLOCKERS, 2018-2030 (USD MILLION)
TABLE 286. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY COMBINATION THERAPY, 2018-2030 (USD MILLION)
TABLE 287. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY PHYTOTHERAPY, 2018-2030 (USD MILLION)
TABLE 288. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY GENERIC STATUS, 2018-2030 (USD MILLION)
TABLE 289. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY BRANDED, 2018-2030 (USD MILLION)
TABLE 290. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 291. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 292. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY CAPSULE, 2018-2030 (USD MILLION)
TABLE 293. NIGERIA BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, BY TABLET, 2018-2030 (USD MILLION)
TABLE 294. EGYPT BENIGN PROSTATIC HYPERTROPHY DRUGS MARKET SIZE, B

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Benign Prostatic Hypertrophy Drugs market report include:
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Boehringer Ingelheim International GmbH
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Limited
  • Lupin Limited

Table Information

Report AttributeDetails
No. of Pages197
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.89 Billion
Forecasted Market Value ( USD ) by 2030 $ 8.26 Billion
Compound Annual Growth Rate7.0%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Benign Prostatic Hypertrophy Medication Market by Product Type, Drug Type, Distribution Channel, Age Group - Global Forecast to 2030 - Product Image

Benign Prostatic Hypertrophy Medication Market by Product Type, Drug Type, Distribution Channel, Age Group - Global Forecast to 2030

  • Report
  • 198 Pages
  • Global
From
Drugs for Benign Prostatic hypertrophy Market Report 2025 - Product Image

Drugs for Benign Prostatic hypertrophy Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032 - Product Image

Benign Prostatic Hyperplasia Treatment Market Report by Treatment Type, and Region 2024-2032

  • Report
  • 148 Pages
  • Global
From
Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment Market Report 2025 - Product Image

Benign Prostatic Hyperplasia (BPH) Treatment Devices and Equipment Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Benign Prostatic Hyperplasia Therapeutics Market by Dosage Form, Distribution Channel, End User, Therapy Type - Global Forecast to 2030 - Product Image

Benign Prostatic Hyperplasia Therapeutics Market by Dosage Form, Distribution Channel, End User, Therapy Type - Global Forecast to 2030

  • Report
  • 194 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.